Skip to main content

Market Overview

Milestone Pharma-Ji Xing Pharma Ink $127M Etripamil Development Agreement For China

Milestone Pharma-Ji Xing Pharma Ink $127M Etripamil Development Agreement For China
  • Milestone Pharmaceuticals Inc (NASDAQ: MISThit a major snag last March when its investigational etripamil nasal spray for episodes of rapid heart rate missed the primary endpoint.
  • A year later, it’s touting new data on its secondary endpoints and a partnership with Ji Xing Pharmaceuticals to develop the candidate in China for paroxysmal supraventricular tachycardia (PSVT) and additional cardiovascular conditions.
  • Ji Xing is paying $15 million upfront and making a $5 million equity investment for the rights to develop and commercialize etripamil, a fast-acting calcium channel blocker, in Greater China.
  • The agreement involves milestone payments of up to $107.5 million.
  • At ACC 2021, Milestone said etripamil had higher scores than placebo related to relief of specific symptoms associated with PSVT, including rapid pulse (p=0.002), palpitations (p<0.001), shortness of breath (p=0.008), dizziness (p=0.012), and anxiety (p=0.006).
  • In addition, a 51% reduction (p=0.051) in need for an emergency room (ER) visit and a 47% prolongation (p<0.05) in time to ER intervention was observed in patients who received etripamil versus placebo.
  • Price Action: MIST shares are down 0.9% at $5.50 during the market session on the last check Monday.

Related Articles (MIST)

View Comments and Join the Discussion!

Posted-In: Briefs Cardiovascular diseaseBiotech News Health Care Contracts FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at